Latest news with #InvestorSummitVirtual
Yahoo
07-03-2025
- Business
- Yahoo
ProPhase Labs to Present at the Investor Summit Virtual on March 11
GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ('ProPhase' or the 'Company'), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this year's Investor Summit Virtual on March 11th. Event: Q1 Investor SummitPresentation Time: 1:30 P.M. ET Location: Conference Overview and StructureThe Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market. This quarter's event is focused on MicroCap companies who are undervalued and have a catalyst. Registration for Investors To request free registration, please go to and click the 'Registration' button. About ProPhase Labs ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Media Relations and Institutional Investor Contact:ProPhase Labs, Retail Investor Relations Contact:Renmark Financial CommunicationsJohn Boidman212-812-7680Jboidman@
Associated Press
06-03-2025
- Business
- Associated Press
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th. About Barinthus Biotherapeutics plc Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Further, it has license, research and development, and collaboration agreements with OUI, NIH, CanSino, CRUK; and Arbutus. Event: Q1 Investor Summit Presentation Time: 11:00 AM ET Conference Overview and Structure The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market. This quarter's event is focused on MicroCap companies who are significantly undervalued and have a near-term catalyst. and click the 'Registration' button. For More Information
